Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.35 |
| ▸ | PRKACA | P17612 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18650891 | 1.00 | GPR119 (0.37) | GPR119LRRK2PTGS2F10RPS6KB1 | |
| SCHEMBL18650892 | 0.87 | LRRK2 (0.35) | GPR119LRRK2PTGS2F10 | |
| SCHEMBL23618026 | 0.85 | PTGS2 (0.41) | LRRK2PTGS2F10RPS6KB1PRKACA | |
| SCHEMBL18650901 | 0.82 | PTGS2 (0.46) | PTGS2F10RPS6KB1PRKACAGSK3B | |
| SCHEMBL23617944 | 0.81 | PTGS2 (0.41) | LRRK2PTGS2F10RPS6KB1PRKACA | |
| SCHEMBL18650889 | 0.81 | LRRK2 (0.34) | GPR119LRRK2PTGS2F10RPS6KB1 | |
| SCHEMBL18650911 | 0.80 | PIK3CA (0.39) | LRRK2PTGS2F10 | |
| SCHEMBL18667872 | 0.80 | PIK3CA (0.39) | LRRK2PTGS2F10 | |
| SCHEMBL18650909 | 0.80 | PTGS2 (0.40) | PTGS2F10RPS6KB1PRKACAGSK3B | |
| SCHEMBL18650886 | 0.79 | LRRK2 (0.36) | GPR119LRRK2PTGS2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350177-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| WO-2017049068-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 1089/4885LRRK2 86/4885PTGS2 3203/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | GPR119 1089/4885LRRK2 86/4885PTGS2 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.